Leukocyte-induced angiogenesis and subcutaneous growth of B16 melanoma

M. Gutman, Rakesh K Singh, S. Yoon, K. Xie, C. D. Bucana, I. J. Fidler

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

We investigated the mechanism(s) by which systemic administration of doxorubicin (DXR) produced growth retardation of B16 melanomas in the subcutis of syngeneic mice. DXR or saline was injected intravenously (i.v.) into C57BL/6 mice, and B16-BL6 cells were implanted subcutaneously (s.c.) on day 3, 7, or 21 after DXR treatment. In the DXR-pretreated mice, the tumors grew at a slower rate than in control (saline-treated) mice. The experiments were repeated with a B16 variant resistant to DXR with similar results. Tumor growth retardation correlated with extent of myelosuppression monitored by counting bone marrow cells, circulating leukocytes and peritoneal macrophages. In DXR-pretreated mice reconstituted with 1 x 107 viable syngeneic spleen cells, the s.c. tumors grew at a rate similar to that in control mice. DXR treatment and spleen cell reconstitution experiments were repeated in BALB/c athymic nude mice. The results were very similar. The growth of s.c. tumors was directly correlated with the degree of peritumoral vascularity. These data indicate that in addition to its well-documented direct antitumor effects, DXR may produce retardation of tumor growth by producing myelosuppression and, hence, inhibition of host cell-induced tumor angiogenesis.

Original languageEnglish (US)
Pages (from-to)163-170
Number of pages8
JournalCancer Biotherapy
Volume9
Issue number2
DOIs
StatePublished - Jan 1 1994

Fingerprint

Experimental Melanomas
Doxorubicin
Leukocytes
Growth
Neoplasms
Nude Mice
Spleen
Peritoneal Macrophages
Inbred C57BL Mouse
Bone Marrow Cells

Keywords

  • angiogenesis
  • doxorubicin
  • myelosuppression

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research

Cite this

Leukocyte-induced angiogenesis and subcutaneous growth of B16 melanoma. / Gutman, M.; Singh, Rakesh K; Yoon, S.; Xie, K.; Bucana, C. D.; Fidler, I. J.

In: Cancer Biotherapy, Vol. 9, No. 2, 01.01.1994, p. 163-170.

Research output: Contribution to journalArticle

Gutman, M, Singh, RK, Yoon, S, Xie, K, Bucana, CD & Fidler, IJ 1994, 'Leukocyte-induced angiogenesis and subcutaneous growth of B16 melanoma', Cancer Biotherapy, vol. 9, no. 2, pp. 163-170. https://doi.org/10.1089/cbr.1994.9.163
Gutman, M. ; Singh, Rakesh K ; Yoon, S. ; Xie, K. ; Bucana, C. D. ; Fidler, I. J. / Leukocyte-induced angiogenesis and subcutaneous growth of B16 melanoma. In: Cancer Biotherapy. 1994 ; Vol. 9, No. 2. pp. 163-170.
@article{d6b1a306820b45f38397a6f259536b91,
title = "Leukocyte-induced angiogenesis and subcutaneous growth of B16 melanoma",
abstract = "We investigated the mechanism(s) by which systemic administration of doxorubicin (DXR) produced growth retardation of B16 melanomas in the subcutis of syngeneic mice. DXR or saline was injected intravenously (i.v.) into C57BL/6 mice, and B16-BL6 cells were implanted subcutaneously (s.c.) on day 3, 7, or 21 after DXR treatment. In the DXR-pretreated mice, the tumors grew at a slower rate than in control (saline-treated) mice. The experiments were repeated with a B16 variant resistant to DXR with similar results. Tumor growth retardation correlated with extent of myelosuppression monitored by counting bone marrow cells, circulating leukocytes and peritoneal macrophages. In DXR-pretreated mice reconstituted with 1 x 107 viable syngeneic spleen cells, the s.c. tumors grew at a rate similar to that in control mice. DXR treatment and spleen cell reconstitution experiments were repeated in BALB/c athymic nude mice. The results were very similar. The growth of s.c. tumors was directly correlated with the degree of peritumoral vascularity. These data indicate that in addition to its well-documented direct antitumor effects, DXR may produce retardation of tumor growth by producing myelosuppression and, hence, inhibition of host cell-induced tumor angiogenesis.",
keywords = "angiogenesis, doxorubicin, myelosuppression",
author = "M. Gutman and Singh, {Rakesh K} and S. Yoon and K. Xie and Bucana, {C. D.} and Fidler, {I. J.}",
year = "1994",
month = "1",
day = "1",
doi = "10.1089/cbr.1994.9.163",
language = "English (US)",
volume = "9",
pages = "163--170",
journal = "Cancer Biotherapy",
issn = "1062-8401",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Leukocyte-induced angiogenesis and subcutaneous growth of B16 melanoma

AU - Gutman, M.

AU - Singh, Rakesh K

AU - Yoon, S.

AU - Xie, K.

AU - Bucana, C. D.

AU - Fidler, I. J.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - We investigated the mechanism(s) by which systemic administration of doxorubicin (DXR) produced growth retardation of B16 melanomas in the subcutis of syngeneic mice. DXR or saline was injected intravenously (i.v.) into C57BL/6 mice, and B16-BL6 cells were implanted subcutaneously (s.c.) on day 3, 7, or 21 after DXR treatment. In the DXR-pretreated mice, the tumors grew at a slower rate than in control (saline-treated) mice. The experiments were repeated with a B16 variant resistant to DXR with similar results. Tumor growth retardation correlated with extent of myelosuppression monitored by counting bone marrow cells, circulating leukocytes and peritoneal macrophages. In DXR-pretreated mice reconstituted with 1 x 107 viable syngeneic spleen cells, the s.c. tumors grew at a rate similar to that in control mice. DXR treatment and spleen cell reconstitution experiments were repeated in BALB/c athymic nude mice. The results were very similar. The growth of s.c. tumors was directly correlated with the degree of peritumoral vascularity. These data indicate that in addition to its well-documented direct antitumor effects, DXR may produce retardation of tumor growth by producing myelosuppression and, hence, inhibition of host cell-induced tumor angiogenesis.

AB - We investigated the mechanism(s) by which systemic administration of doxorubicin (DXR) produced growth retardation of B16 melanomas in the subcutis of syngeneic mice. DXR or saline was injected intravenously (i.v.) into C57BL/6 mice, and B16-BL6 cells were implanted subcutaneously (s.c.) on day 3, 7, or 21 after DXR treatment. In the DXR-pretreated mice, the tumors grew at a slower rate than in control (saline-treated) mice. The experiments were repeated with a B16 variant resistant to DXR with similar results. Tumor growth retardation correlated with extent of myelosuppression monitored by counting bone marrow cells, circulating leukocytes and peritoneal macrophages. In DXR-pretreated mice reconstituted with 1 x 107 viable syngeneic spleen cells, the s.c. tumors grew at a rate similar to that in control mice. DXR treatment and spleen cell reconstitution experiments were repeated in BALB/c athymic nude mice. The results were very similar. The growth of s.c. tumors was directly correlated with the degree of peritumoral vascularity. These data indicate that in addition to its well-documented direct antitumor effects, DXR may produce retardation of tumor growth by producing myelosuppression and, hence, inhibition of host cell-induced tumor angiogenesis.

KW - angiogenesis

KW - doxorubicin

KW - myelosuppression

UR - http://www.scopus.com/inward/record.url?scp=0028173742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028173742&partnerID=8YFLogxK

U2 - 10.1089/cbr.1994.9.163

DO - 10.1089/cbr.1994.9.163

M3 - Article

VL - 9

SP - 163

EP - 170

JO - Cancer Biotherapy

JF - Cancer Biotherapy

SN - 1062-8401

IS - 2

ER -